Nanyang Biologics Joins NVIDIA & Tribe’s Prestigious Ignition Program

Nanyang Biologics harnesses NVIDIA AI and accelerated computing to transform $7 billion drug discovery industry.

‍

Nanyang Biologics, an AI-powered drug discovery startup, has achieved a major breakthrough in its proprietary DTIGN (Drug-Target Interaction Graph Neural Network) platform. In recognition of this advancement, NVIDIA and Tribe have selected Nanyang Biologics for the inaugural Ignition AI Accelerator, an exclusive initiative designed to accelerate top AI startups that are pushing the boundaries of AI development. Nanyang Biologics is one of the only five startups in Asia - Pacific to be selected in this first batch, highlighting its leadership in AI-driven pharmaceutical research.

‍

Ignition AI Accelerator: The World’s Elite Innovation Program

‍

The Ignition AI Accelerator is a premier initiative designed to empower startups with access to world-class AI resources, computing infrastructure, industry mentorship, and strategic collaborations. As part of this initiative, NVIDIA and Tribe have engaged major pharmaceutical leaders, including Pfizer, which has officially announced its participation, to provide comprehensive support encompassing businesses, technical and go-to-market guidance. This program is set to strengthen the connection between AI innovation and real-world drug discovery, optimizing research processes and accelerating the development of life-saving treatments.

‍

Fueling Innovation: How the Ignition Program Propels Nanyang Biologics Forward

‍

Through the Ignition Program, Nanyang Biologics will gain access to NVIDIA’s cutting-edge AI tools and resources, enabling Nanyang Biologics to scale its computational capabilities and process vast amounts of data more efficiently, significantly accelerating the drug discovery process. Additionally, NVIDIA’s expertise in AI and machine learning will provide Nanyang Biologics with valuable insights and guidance, helping to refine and optimize the DTIGN platform. 

‍

Not only that, the program also provides Nanyang Biologics with an approach to a vibrant ecosystem of startups, researchers, and industry experts, fostering collaboration and knowledge-sharing. Through distribution networks, opportunities showcase, and market amplification, making it easier for pharmaceutical companies and research institutions to adopt cutting-edge AI technologies for drug discovery.

‍

This endeavor demonstrates Nanyang Biologics’s unwavering dedication to advancing biotech innovation and accelerating cutting-edge AI solutions in drug discovery and beyond. “Being part of the Ignition AI Accelerator confirms Nanyang Biologics’ position at the forefront of AI-driven drug discovery” said Giang Nguyen, CTO of Nanyang Biologics. “With NVIDIA and Tribe’s support and the involvement of global leaders like Pfizer, we are transforming pharmaceutical R&D by reducing novel bioactive compound discovery timelines, increasing efficiency, and accelerating the development of life-saving treatments.”

‍

Advancing Drug Discovery with AI

‍

The drug discovery process is notoriously time-consuming and expensive, often taking more than a decade and costing billions of dollars to bring a single drug to market. AI has the potential to revolutionize this process by enabling researchers to analyze vast amounts of data, identify promising drug candidates, and predict their efficacy and safety with greater accuracy.

‍

Nanyang Biologics’s DTIGN platform is at the forefront of this transformation. By combining advanced AI algorithms with high-performance computing, DTIGN can accelerate the compounds screening phase, identify potential drug candidates, and optimize their properties for further development. This not only reduces the time and cost of drug discovery but also increases the likelihood of success, ultimately leading to better treatments for patients.

‍

By leveraging Graph Neural Networks (GNNs), Self-Attention Mechanisms, and Semi-Supervised Learning, DTIGN accurately predicts complex drug-target interactions. Recent advancements have led to a 27.03% improvement in bioactivity prediction accuracy, a 64-fold increase in hit rate efficiency, and a 68.2% reduction in drug discovery timelines compared to traditional methods, significantly accelerating the development of novel therapeutics. 

‍

What sets DTIGN apart is its AI-powered approach to bioactivity prediction, which achieves greater accuracy and depth than conventional methods. Most AI-driven drug discovery platforms rely on ligand-based models that focus only on a drug’s structure without assessing how it interacts with biological targets. These models often overlook key molecular interactions and environmental factors, reducing predictive reliability.

‍

DTIGN surpasses these limitations by incorporating not only drug-protein interactions but also critical biological and pharmacological factors, including signaling pathways, reaction environments, pharmacokinetics, and species differences. This comprehensive analysis enhances hit rates and increases the likelihood of identifying successful drug candidates.

‍

Beyond its advanced AI model, Nanyang Biologics expands therapeutic possibilities through natural compound research. Unlike platforms that depend solely on synthetic libraries, the company integrates AI-driven predictions with an extensive repository of bioactive compounds from nature, unlocking new opportunities for breakthrough treatments.

‍

Gaining access to NVIDIA’s deep AI resources and expertise will further enhance the capabilities of DTIGN, enabling it to process even larger database and perform more complex simulations. This will allow Nanyang Biologics to tackle more challenging drug discovery projects, including those involving rare diseases and complex biological targets.

‍

What’s Next?

‍

Nanyang Biologics is looking for commercial collaborations with pharmaceutical companies that are focused on drug discovery, particularly in cancer and cardiovascular research. Beyond pharmaceuticals, we are looking to collaborate with universities and technological institutes engaged in molecular research. 

‍

These partnerships aim to speed up the discovery of new therapeutic compounds and enhance the precision of drug design, culminating in breakthroughs that could improve patient care. By integrating their AI solutions into academic and institutional settings, Nanyang Biologics can empower research teams to tackle complex scientific challenges.

‍

About Nanyang Biologics

Nanyang Biologics is an AI-driven biotech company dedicated to advancing drug discovery. By combining machine learning, high-performance computing, and pharmaceutical expertise, the company accelerates research in cancer, metabolic disorders, and neurodegenerative diseases. Through strategic partnerships with NVIDIA and Tribe, Nanyang Biologics continues to push the limits of AI-driven pharmaceutical innovation, optimizing drug development and reducing discovery timelines.